Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S ADVIL FLAVORED versus MEFENAMIC ACID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S ADVIL FLAVORED versus MEFENAMIC ACID.
CHILDREN'S ADVIL-FLAVORED vs MEFENAMIC ACID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, resulting in antipyretic, analgesic, and anti-inflammatory effects.
Reversible inhibition of cyclooxygenase (COX-1 and COX-2) leading to decreased prostaglandin synthesis; exhibits both central and peripheral analgesic effects.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription, up to 3200 mg/day under medical supervision.
500 mg orally as an initial dose, followed by 250 mg every 6 hours as needed, not to exceed 1 week.
None Documented
None Documented
2-4 hours in children; prolonged in neonates (up to 30 hours) and hepatic impairment.
Clinical Note
moderateMefenamic acid + Gatifloxacin
"Mefenamic acid may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateMefenamic acid + Rosoxacin
"Mefenamic acid may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateMefenamic acid + Levofloxacin
"Mefenamic acid may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateMefenamic acid + Trovafloxacin
Terminal half-life is 2-4 hours; prolonged in hepatic impairment and overdose.
Renal excretion of conjugated metabolites (75-80% as glucuronide and sulfate conjugates, <10% as unchanged drug); biliary/fecal elimination accounts for <5%.
Primarily renal (52% as glucuronide metabolites, <6% unchanged) and fecal (20-30% via biliary elimination).
Category C
Category D/X
NSAID
NSAID
"Mefenamic acid may increase the neuroexcitatory activities of Trovafloxacin."